

To: [REDACTED] [JRDNL][REDACTED]@its.jnj.com
From: [REDACTED]
Sent: Thur 2/4/2021 8:38:20 AM
Subject: RE: Request from Dutch government to prepare for questions from Parliament around site selection
Received: Thur 2/4/2021 8:38:20 AM

Dank!

Verzonden met BlackBerry Work
 (www.blackberry.com)

Van: [REDACTED] [JRDNL] <[REDACTED]@its.jnj.com>
Datum: woensdag 03 feb. 2021 11:27 PM
Aan: [REDACTED] <[REDACTED]@minvws.nl>
Kopie: [REDACTED] [JRDNL] <[REDACTED]@its.jnj.com>, [REDACTED] [JRDNL] <[REDACTED]@its.jnj.com>, [REDACTED] [JACNL] <[REDACTED]@its.jnj.com>, [REDACTED] [JRDNL] <[REDACTED]@its.jnj.com>
Onderwerp: RE: Request from Dutch government to prepare for questions from Parliament around site selection

Beste [REDACTED]

Bullet-wise:

- Na de screening van mogelijke productiesites, waaronder die van [REDACTED] zijn die sites geïdentificeerd die de beste fit hadden met onze criteria rond 1. procestechnische eisen voor productie van ons vaccin, 2. capaciteit (volume), 3. vermogen om op te starten en op te schalen conform onze timelines
- Inmiddels zijn we bezig om op basis van deze sites een wereldwijd productie netwerk op te bouwen, op te starten en op te schalen
- We blijven samenwerken met overheden en andere partners om verdere mogelijkheden te evalueren, maar iedere site die nu nog geselecteerd wordt zal geen (of slechts een zeer beperkte) bijdrage kunnen leveren aan de productie in 2021
- Dit geldt helaas ook voor [REDACTED]
- We gaan opnieuw in overleg met [REDACTED] om een mogelijke samenwerking voor 2022 een daarna te verkennen.
- Ik kan echter niet uitsluiten dat er internationaal gezien nog andere potentiële sites zijn, die nog niet in ons netwerk zitten, en die een betere fit hebben met onze criteria.

In kort:

- Voor 2021 zijn we afhankelijk van het netwerk dat we nu aan het opbouwen, opstarten en opschalen zijn.
- De beste ondersteuning die de overheid (NL en/of EU) ons kan bieden is hulp bij het zeker stellen van een ononderbroken stroom van goederen tussen de verschillende sites in het netwerk omdat er steeds meerdere sites betrokken zijn bij de productie van het uiteindelijke vaccin.

Mvg, [REDACTED]

Kind regards / Met vriendelijke groet

[REDACTED]



Janssen Vaccines and Prevention B.V.
 Archimedesweg 4-6, 2333 CN Leiden, The Netherlands
 PO Box 2048, 2301 CA Leiden, The Netherlands
 Mobile: +31 [REDACTED]
 Phone office: +31 [REDACTED]
 [REDACTED]@its.jnj.com

Confidentiality Notice: This e-mail transmission is confidential and may be privileged information that is intended only for the individual or entity named in the e-mail address. If you are not the intended recipient and believe you have received this e-mail transmission in error, please reply to the sender, so that we can arrange for proper delivery, and then please delete the message from your inbox. The unauthorized use, dissemination, distribution or reproduction of this e-mail, including attachments, is prohibited and may be unlawful. Receipt by anyone other than the intended recipient(s) is not a waiver of any attorney/client or other privilege. Thank you.

From: 5.1.2e <5.1.2e@minvws.nl>
Sent: woensdag 3 februari 2021 18:21
To: 5.1.2e [JRDNL] <5.1.2e@its.jnj.com>
Cc: 5.1.2e [JRDNL] <5.1.2e@its.jnj.com>; 5.1.2e [JRDNL] <5.1.2e@its.jnj.com>; 5.1.2e [JACNL] <5.1.2e@its.jnj.com>
Subject: [EXTERNAL] RE: Request from Dutch government to prepare for questions from Parliament around site selection

WARNING: This email originated from outside the company. Do not click on links unless you recognize the sender and have confidence the content is safe. If you have concerns about this email, send it as an attachment to 5.1.2e @ITS.JNJ.COM.

Dank je 5.1.2e

De vraag die mogelijk nog volgt zal zijn:

“Wat kan Nederland of de EU doen om Janssen te helpen om de capaciteit van bedrijven als 5.1.1c zo snel en goed mogelijk in te zetten, voor de opschaling van de productiecapaciteit van Janssen?”

Ik hoor het graag als jullie daar nog een reactie op hebben.

Groet,
 5.1.2e

Van: 5.1.2e [JRDNL] <5.1.2e@its.jnj.com>
Verzonden: woensdag 3 februari 2021 18:05
Aan: 5.1.2e <5.1.2e@minvws.nl>
CC: 5.1.2e [JRDNL] <5.1.2e@its.jnj.com>; 5.1.2e [JRDNL] <5.1.2e@its.jnj.com>; 5.1.2e [JACNL] <5.1.2e@its.jnj.com>; 5.1.2e [JRDNL] <5.1.2e@its.jnj.com>; 5.1.2e [JACNL] <5.1.2e@its.jnj.com>
Onderwerp: Request from Dutch government to prepare for questions from Parliament around site selection

Beste 5.1.2e

Bijgaand een serie talking points mbt de vragen:

5.1.5

Neem gerust contact op als je nog vragen hebt.

Mocht de Minister of andere medewerkers van het Departement behoefte hebben aan een mondelinge briefing dan ben ik daarvoor beschikbaar.

Mvg, 5.1.2e

On the question “Why is Janssen not using 5.1.1c to support the fill/finish operations for it’s Covid-19 vaccine?”

- To achieve our ambitious goals to deliver at a rate of one billion doses of our COVID-19 vaccine, we have focused since early 2020 on building a global supply network in parallel to developing our vaccine candidate.
- This global vaccine supply network features multiple manufacturing sites that are involved in the production of the vaccine candidate across different facilities, sometimes in different countries, before the vaccine can be distributed globally if authorized for use by health authorities.
- We continue to activate new manufacturing sites in this supply network as quickly as Health Authority approvals allow. Validation and certification of production facilities is a key component of the quality standards set by our company and the health authorities

- From the start collaboration is a central part of our approach. We have partnered with governments, health authorities and other companies to enable the global supply of and access to our vaccine candidate, if authorized for use by health authorities.

- We will continue to work with governments and other partners to evaluate opportunities to, but any additional sites selected now would not yield any product until late 2021.

On the site selection process

- We have established a global network of partners in less than a year that can support our commitments - this would normally take years to build

- We have assessed over 5.1.1c Sites across the world, from which over 5.1.1c from EMEA, based on criteria (Technical needs, volume, timelines). 5.1.1c was one of these sites

- We have finally selected those sites that based on their capabilities, capacities and ability were able to support the accelerated timelines and global network in 2020 and we have been executing since then with full force

Global Manufacturing Collaborations

Given the unprecedented nature of the pandemic, Johnson & Johnson is expanding its global manufacturing capacity. We have established new U.S. vaccine manufacturing capabilities and are scaling up capacity in other countries.

In addition to our existing manufacturing capacity in Leiden, the Netherlands, we have entered into multiple agreements to expand our manufacturing capability of our COVID-19 vaccine candidate.

5.1.1c

Kind regards / Met vriendelijke groet

5.1.2e



5.1.2e

Archimedesweg 4-6, 2333 CN Leiden, The Netherlands

PO Box 2048, 2301 CA Leiden, The Netherlands

Mobile: +31 5.1.2e

Phone office: +31 5.1.2e

5.1.2e [@its.jnj.com](mailto:5.1.2e@its.jnj.com)

Confidentiality Notice: This e-mail transmission is confidential and may be privileged information that is intended only for the individual or entity named in the e-mail address. If you are not the intended recipient and believe you have received this e-mail transmission in error, please reply to the sender, so that we can arrange for proper delivery, and then please delete the message from your inbox. The unauthorized use, dissemination, distribution or reproduction of this e-mail, including attachments, is prohibited and may be unlawful. Receipt by anyone other than the intended recipient(s) is not a waiver of any attorney/client or other privilege. Thank you.